S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   312.04 (-0.73%)
AAPL   127.29 (-1.26%)
MSFT   212.96 (-0.03%)
FB   251.63 (+2.44%)
GOOGL   1,730.63 (-0.02%)
AMZN   3,103.58 (-0.76%)
TSLA   827.07 (-2.12%)
NVDA   514.92 (-2.48%)
BABA   242.79 (-0.08%)
CGC   33.52 (-3.18%)
GE   11.35 (-2.66%)
MU   80.57 (-0.90%)
AMD   88.25 (-2.80%)
T   29.19 (-0.34%)
NIO   56.13 (-7.79%)
F   9.87 (-2.95%)
ACB   11.93 (-0.25%)
BA   204.89 (-2.39%)
DIS   171.14 (-1.32%)
NFLX   498.38 (-0.50%)
GILD   63.36 (+1.54%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   312.04 (-0.73%)
AAPL   127.29 (-1.26%)
MSFT   212.96 (-0.03%)
FB   251.63 (+2.44%)
GOOGL   1,730.63 (-0.02%)
AMZN   3,103.58 (-0.76%)
TSLA   827.07 (-2.12%)
NVDA   514.92 (-2.48%)
BABA   242.79 (-0.08%)
CGC   33.52 (-3.18%)
GE   11.35 (-2.66%)
MU   80.57 (-0.90%)
AMD   88.25 (-2.80%)
T   29.19 (-0.34%)
NIO   56.13 (-7.79%)
F   9.87 (-2.95%)
ACB   11.93 (-0.25%)
BA   204.89 (-2.39%)
DIS   171.14 (-1.32%)
NFLX   498.38 (-0.50%)
GILD   63.36 (+1.54%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   312.04 (-0.73%)
AAPL   127.29 (-1.26%)
MSFT   212.96 (-0.03%)
FB   251.63 (+2.44%)
GOOGL   1,730.63 (-0.02%)
AMZN   3,103.58 (-0.76%)
TSLA   827.07 (-2.12%)
NVDA   514.92 (-2.48%)
BABA   242.79 (-0.08%)
CGC   33.52 (-3.18%)
GE   11.35 (-2.66%)
MU   80.57 (-0.90%)
AMD   88.25 (-2.80%)
T   29.19 (-0.34%)
NIO   56.13 (-7.79%)
F   9.87 (-2.95%)
ACB   11.93 (-0.25%)
BA   204.89 (-2.39%)
DIS   171.14 (-1.32%)
NFLX   498.38 (-0.50%)
GILD   63.36 (+1.54%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   312.04 (-0.73%)
AAPL   127.29 (-1.26%)
MSFT   212.96 (-0.03%)
FB   251.63 (+2.44%)
GOOGL   1,730.63 (-0.02%)
AMZN   3,103.58 (-0.76%)
TSLA   827.07 (-2.12%)
NVDA   514.92 (-2.48%)
BABA   242.79 (-0.08%)
CGC   33.52 (-3.18%)
GE   11.35 (-2.66%)
MU   80.57 (-0.90%)
AMD   88.25 (-2.80%)
T   29.19 (-0.34%)
NIO   56.13 (-7.79%)
F   9.87 (-2.95%)
ACB   11.93 (-0.25%)
BA   204.89 (-2.39%)
DIS   171.14 (-1.32%)
NFLX   498.38 (-0.50%)
GILD   63.36 (+1.54%)
Log in
NYSE:GEN

Genesis Healthcare Competitors

$0.73
-0.02 (-3.19 %)
(As of 01/15/2021 03:51 PM ET)
Add
Compare
Today's Range
$0.68
Now: $0.73
$0.74
50-Day Range
$0.48
MA: $0.55
$0.77
52-Week Range
$0.40
Now: $0.73
$1.86
Volume116,418 shs
Average Volume3.74 million shs
Market Capitalization$121.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.64

Competitors

Genesis Healthcare (NYSE:GEN) Vs. XBIT, APLT, TORC, SNDL, CRNX, and CO

Should you be buying GEN stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Genesis Healthcare, including XBiotech (XBIT), Applied Therapeutics (APLT), resTORbio (TORC), Sundial Growers (SNDL), Crinetics Pharmaceuticals (CRNX), and Global Cord Blood (CO).

XBiotech (NASDAQ:XBIT) and Genesis Healthcare (NYSE:GEN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Valuation & Earnings

This table compares XBiotech and Genesis Healthcare's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XBiotechN/AN/A$668.63 millionN/AN/A
Genesis Healthcare$4.57 billion0.03$14.62 millionN/AN/A

XBiotech has higher earnings, but lower revenue than Genesis Healthcare.

Profitability

This table compares XBiotech and Genesis Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
XBiotechN/A-7.07%-6.67%
Genesis Healthcare-1.52%-5.06%-1.24%

Insider & Institutional Ownership

14.8% of XBiotech shares are owned by institutional investors. Comparatively, 12.6% of Genesis Healthcare shares are owned by institutional investors. 31.0% of XBiotech shares are owned by company insiders. Comparatively, 36.6% of Genesis Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

XBiotech has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Genesis Healthcare has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for XBiotech and Genesis Healthcare, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
XBiotech00103.00
Genesis Healthcare01002.00

XBiotech currently has a consensus price target of $18.00, indicating a potential upside of 9.89%. Genesis Healthcare has a consensus price target of $0.57, indicating a potential downside of 19.73%. Given XBiotech's stronger consensus rating and higher probable upside, analysts plainly believe XBiotech is more favorable than Genesis Healthcare.

Summary

XBiotech beats Genesis Healthcare on 7 of the 12 factors compared between the two stocks.

Applied Therapeutics (NASDAQ:APLT) and Genesis Healthcare (NYSE:GEN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Valuation & Earnings

This table compares Applied Therapeutics and Genesis Healthcare's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied TherapeuticsN/AN/A$-45,510,000.00($3.55)-6.17
Genesis Healthcare$4.57 billion0.03$14.62 millionN/AN/A

Genesis Healthcare has higher revenue and earnings than Applied Therapeutics.

Profitability

This table compares Applied Therapeutics and Genesis Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied TherapeuticsN/A-85.39%-70.42%
Genesis Healthcare-1.52%-5.06%-1.24%

Insider & Institutional Ownership

54.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 12.6% of Genesis Healthcare shares are owned by institutional investors. 31.5% of Applied Therapeutics shares are owned by company insiders. Comparatively, 36.6% of Genesis Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Applied Therapeutics has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Genesis Healthcare has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Applied Therapeutics and Genesis Healthcare, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Therapeutics00503.00
Genesis Healthcare01002.00

Applied Therapeutics currently has a consensus price target of $63.50, indicating a potential upside of 179.37%. Genesis Healthcare has a consensus price target of $0.57, indicating a potential downside of 19.73%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Genesis Healthcare.

Summary

Genesis Healthcare beats Applied Therapeutics on 7 of the 12 factors compared between the two stocks.

resTORbio (NASDAQ:TORC) and Genesis Healthcare (NYSE:GEN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Valuation & Earnings

This table compares resTORbio and Genesis Healthcare's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
resTORbioN/AN/A$-82,740,000.00($2.41)-5.57
Genesis Healthcare$4.57 billion0.03$14.62 millionN/AN/A

Genesis Healthcare has higher revenue and earnings than resTORbio.

Profitability

This table compares resTORbio and Genesis Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
resTORbioN/A-78.12%-71.63%
Genesis Healthcare-1.52%-5.06%-1.24%

Insider & Institutional Ownership

46.2% of resTORbio shares are owned by institutional investors. Comparatively, 12.6% of Genesis Healthcare shares are owned by institutional investors. 11.8% of resTORbio shares are owned by company insiders. Comparatively, 36.6% of Genesis Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

resTORbio has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500. Comparatively, Genesis Healthcare has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for resTORbio and Genesis Healthcare, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
resTORbio10102.00
Genesis Healthcare01002.00

resTORbio currently has a consensus price target of $4.00, indicating a potential downside of 70.19%. Genesis Healthcare has a consensus price target of $0.57, indicating a potential downside of 19.73%. Given Genesis Healthcare's higher probable upside, analysts plainly believe Genesis Healthcare is more favorable than resTORbio.

Summary

Genesis Healthcare beats resTORbio on 7 of the 11 factors compared between the two stocks.

Sundial Growers (NASDAQ:SNDL) and Genesis Healthcare (NYSE:GEN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Profitability

This table compares Sundial Growers and Genesis Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sundial Growers-362.49%-179.71%-79.40%
Genesis Healthcare-1.52%-5.06%-1.24%

Analyst Recommendations

This is a summary of current recommendations and price targets for Sundial Growers and Genesis Healthcare, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sundial Growers13001.75
Genesis Healthcare01002.00

Sundial Growers currently has a consensus price target of $1.25, indicating a potential upside of 74.36%. Genesis Healthcare has a consensus price target of $0.57, indicating a potential downside of 19.73%. Given Sundial Growers' higher probable upside, analysts plainly believe Sundial Growers is more favorable than Genesis Healthcare.

Valuation & Earnings

This table compares Sundial Growers and Genesis Healthcare's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sundial Growers$75.86 million6.62$-204,570,000.00N/AN/A
Genesis Healthcare$4.57 billion0.03$14.62 millionN/AN/A

Genesis Healthcare has higher revenue and earnings than Sundial Growers.

Insider & Institutional Ownership

10.7% of Sundial Growers shares are owned by institutional investors. Comparatively, 12.6% of Genesis Healthcare shares are owned by institutional investors. 36.6% of Genesis Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Sundial Growers has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Genesis Healthcare has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.

Summary

Genesis Healthcare beats Sundial Growers on 9 of the 12 factors compared between the two stocks.

Genesis Healthcare (NYSE:GEN) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Profitability

This table compares Genesis Healthcare and Crinetics Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genesis Healthcare-1.52%-5.06%-1.24%
Crinetics PharmaceuticalsN/A-43.35%-39.73%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Genesis Healthcare and Crinetics Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genesis Healthcare01002.00
Crinetics Pharmaceuticals01202.67

Genesis Healthcare currently has a consensus price target of $0.57, indicating a potential downside of 19.73%. Crinetics Pharmaceuticals has a consensus price target of $36.00, indicating a potential upside of 149.48%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Genesis Healthcare.

Valuation and Earnings

This table compares Genesis Healthcare and Crinetics Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genesis Healthcare$4.57 billion0.03$14.62 millionN/AN/A
Crinetics Pharmaceuticals$1.19 million396.45$-50,420,000.00($2.09)-6.86

Genesis Healthcare has higher revenue and earnings than Crinetics Pharmaceuticals.

Insider & Institutional Ownership

12.6% of Genesis Healthcare shares are owned by institutional investors. Comparatively, 92.2% of Crinetics Pharmaceuticals shares are owned by institutional investors. 36.6% of Genesis Healthcare shares are owned by insiders. Comparatively, 7.1% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Genesis Healthcare has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.

Summary

Genesis Healthcare beats Crinetics Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Genesis Healthcare (NYSE:GEN) and Global Cord Blood (NYSE:CO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Profitability

This table compares Genesis Healthcare and Global Cord Blood's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genesis Healthcare-1.52%-5.06%-1.24%
Global Cord Blood42.17%12.77%6.91%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Genesis Healthcare and Global Cord Blood, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genesis Healthcare01002.00
Global Cord Blood0000N/A

Genesis Healthcare currently has a consensus price target of $0.57, indicating a potential downside of 19.73%. Given Genesis Healthcare's higher probable upside, equities research analysts plainly believe Genesis Healthcare is more favorable than Global Cord Blood.

Valuation and Earnings

This table compares Genesis Healthcare and Global Cord Blood's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genesis Healthcare$4.57 billion0.03$14.62 millionN/AN/A
Global Cord Blood$172.50 million2.77$66.48 millionN/AN/A

Global Cord Blood has lower revenue, but higher earnings than Genesis Healthcare.

Insider & Institutional Ownership

12.6% of Genesis Healthcare shares are owned by institutional investors. 36.6% of Genesis Healthcare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Genesis Healthcare has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500.

Summary

Global Cord Blood beats Genesis Healthcare on 6 of the 11 factors compared between the two stocks.


Genesis Healthcare Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
XBiotech logo
XBIT
XBiotech
1.3$16.27-3.8%$494.22 millionN/A1.13
APLT
Applied Therapeutics
1.4$21.90-0.5%$490.01 millionN/A-4.60Analyst Upgrade
resTORbio logo
TORC
resTORbio
1.0$13.42-1.1%$489.21 millionN/A-7.41
SNDL
Sundial Growers
1.3$0.71-2.8%$487.81 million$75.86 million-0.24
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.6$14.33-3.1%$486.59 million$1.19 million-5.97
Global Cord Blood logo
CO
Global Cord Blood
0.9$3.93-1.8%$486.20 million$172.50 million6.66
Surface Oncology logo
SURF
Surface Oncology
0.9$12.37-3.4%$486.09 million$15.36 million-14.06Increase in Short Interest
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$6.49-2.6%$485.86 millionN/A-14.75
OYST
Oyster Point Pharma
1.7$17.96-3.3%$479.85 millionN/A-1.64
IDYA
IDEAYA Biosciences
1.5$16.89-3.3%$475.00 millionN/A-8.98
MIRM
Mirum Pharmaceuticals
1.9$18.27-1.0%$474.74 millionN/A-5.31
SeaSpine logo
SPNE
SeaSpine
1.3$16.69-2.7%$473.63 million$159.08 million-8.60Analyst Report
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.7$13.33-8.6%$473.02 millionN/A-10.33Unusual Options Activity
KLDO
Kaleido Biosciences
1.3$13.27-1.4%$470.65 millionN/A-5.25Analyst Report
Decrease in Short Interest
Heavy News Reporting
RCEL
AVITA Medical
1.3$22.74-4.5%$469.44 million$14.26 million-10.99Analyst Revision
Heavy News Reporting
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$8.97-0.4%$466.59 million$2.91 million-3.13
Nabriva Therapeutics logo
NBRV
Nabriva Therapeutics
1.1$2.90-5.2%$459.90 million$9.48 million-0.49Analyst Downgrade
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$3.06-3.6%$458.19 million$335 million-1.03
Accuray logo
ARAY
Accuray
2.2$4.73-5.1%$453.63 million$382.93 million33.79
Spero Therapeutics logo
SPRO
Spero Therapeutics
1.5$16.49-0.8%$452.12 million$18.15 million-3.80Analyst Downgrade
BCYC
Bicycle Therapeutics
1.1$26.99-5.5%$451.25 million$13.80 million-13.04Analyst Report
Proteon Therapeutics logo
PRTO
Proteon Therapeutics
0.8$20.14-2.8%$446.69 millionN/A-17.51
Fluidigm logo
FLDM
Fluidigm
1.8$6.21-3.9%$442.49 million$117.24 million-9.27Decrease in Short Interest
XOMA logo
XOMA
XOMA
1.4$39.63-0.9%$440.66 million$18.37 million-35.70Decrease in Short Interest
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$4.31-0.9%$439.83 million$111.39 million30.79Analyst Revision
Heavy News Reporting
AC Immune logo
ACIU
AC Immune
1.3$5.91-3.6%$439.06 million$111.75 million-6.57
Wave Life Sciences logo
WVE
Wave Life Sciences
1.8$9.14-1.9%$437.54 million$15.98 million-1.61Analyst Upgrade
Puma Biotechnology logo
PBYI
Puma Biotechnology
1.4$10.82-1.7%$437.38 million$272.30 million-10.02
UroGen Pharma logo
URGN
UroGen Pharma
1.9$20.08-4.2%$437.37 million$20,000.00-3.27Analyst Report
Heavy News Reporting
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.30-0.2%$436.82 million$56.50 million0.00
Computer Programs and Systems logo
CPSI
Computer Programs and Systems
1.6$29.03-2.9%$433.62 million$274.63 million18.85Decrease in Short Interest
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.39-4.0%$431.66 million$49.65 million-1.92
DURECT logo
DRRX
DURECT
1.4$2.04-3.4%$428.71 million$29.56 million-40.79Analyst Downgrade
ETNB
89bio
1.6$21.33-1.1%$428.59 millionN/A-4.22Analyst Downgrade
CymaBay Therapeutics logo
CBAY
CymaBay Therapeutics
1.6$6.07-2.3%$427.79 millionN/A-6.46
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.8$7.48-0.4%$421.12 million$6.07 million-3.58Analyst Downgrade
Increase in Short Interest
OrganiGram logo
OGI
OrganiGram
1.6$1.81-0.3%$417.76 million$64.61 million-3.22Earnings Announcement
Analyst Downgrade
Decrease in Short Interest
Analyst Revision
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$8.44-1.4%$413.49 millionN/A-4.33Analyst Downgrade
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.3$3.41-2.3%$412.73 million$4.13 million-7.58
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.65-33.8%$410.87 million$14.75 million-2.42Analyst Report
Increase in Short Interest
Heavy News Reporting
Verastem logo
VSTM
Verastem
1.8$2.47-2.0%$410.85 million$17.46 million-1.75Increase in Short Interest
TFFP
TFF Pharmaceuticals
1.4$17.69-3.2%$405.62 millionN/A-5.71Analyst Report
The Joint logo
JYNT
The Joint
1.5$28.46-1.1%$403.96 million$48.45 million105.41
Selecta Biosciences logo
SELB
Selecta Biosciences
1.7$3.53-4.5%$398.63 million$6.68 million-3.53
Athersys logo
ATHX
Athersys
1.3$1.92-4.7%$397.38 million$5.63 million-5.19Analyst Upgrade
NantHealth logo
NH
NantHealth
0.6$3.57-0.0%$397.03 million$95.96 million-8.11Analyst Upgrade
Increase in Short Interest
Heavy News Reporting
ANI Pharmaceuticals logo
ANIP
ANI Pharmaceuticals
1.9$32.22-0.4%$396.69 million$206.55 million-16.19
Anavex Life Sciences logo
AVXL
Anavex Life Sciences
1.3$5.81-1.9%$396.42 millionN/A-12.91
American Renal Associates logo
ARA
American Renal Associates
1.0$11.47-0.1%$396.21 million$822.52 million-22.06Decrease in Short Interest
Heavy News Reporting
BeyondSpring logo
BYSI
BeyondSpring
1.2$12.86-0.7%$395.18 millionN/A-6.30Analyst Downgrade
Decrease in Short Interest
This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.